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CC BY-NC-ND license (http://creativAbstract Background/Purpose: The objective of this study is to determine whether tacroli-
mus trough level is appropriate for therapeutic drug monitoring (TDM) of Advagraf in stable
Chinese kidney transplant recipients (KTRs).
Methods: In this single-center pharmacokinetic study, stable adult Chinese KTRs on Advagraf
were recruited and their blood tacrolimus levels measured at 12 time points within 24 hours.
Trough level was defined as predose drug level (C0). The pharmacokinetic parameters were
calculated using standardized noncompartmental methods. Drug exposure, defined as 24-
hour area under the curve (AUC0e24), was calculated using the linear trapezoidal method.
Whole blood tacrolimus level measurement was performed by high-performance liquid chro-
matography/tandem mass spectrophotometry.
Results: Fourteen patients (8 males; mean age, 47.1  9.2 years; mean duration of transplant,
8.3  3.6 years) completed the study. The mean C0 was 4.4  1.9 ng/mL, and the mean AUC0
e24 was 143.8  57.0 ng h/mL. The mean maximum concentration (Cmax) was 10.2  3.9 ng/
mL, and the median time to Cmax was 2.0 hours (interquartile range, 1.0e3.0 hours). There
was a strong correlation between C0 and AUC0e24 (rZ 0.90, p < 0.001). Patients receiving dil-
tiazem had higher mean AUC0e24 (153.0  55.3 ng h/mL vs. 110.1  60.1 ng h/mL) despite a
lower dose (mean tacrolimus dose, 0.039  0.022 mg/kg/d vs. 0.054  0.021 mg/kg/d),
although both differences did not reach statistical significance. Apart from C0, tacrolimus level
obtained from 6 hours to 12 hours (C6 to C12) also had good correlation with AUC0e24.
Conclusion: Tacrolimus trough level is a good surrogate marker for TDM of Advagraf in stable
Chinese KTRs. The role of C6 to C12 in TDM remains to be determined.t of Medicine & Therapeutics, 9th floor, Lui Che Woo Clinical Sciences Building, Prince of Wales
al Administrative Region.
.hk (C.C. Szeto).
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of Nephrology. Published by Elsevier (Singapore) Pte Ltd. This is an open access article under the
ecommons.org/licenses/by-nc-nd/4.0/).
2 T.K.-W. Ma et al.背景 / 目的: 本研究旨在調查在病情穩定的華裔腎臟移植接受者 (KTRs) 間,Cmin 是否適用於藥物
血中濃度監測 (TDM)。
方法: 在這一項單中心藥物動力學研究中,對象為病情穩定的華裔 KTRs,在 24 小時內 12 個時間點
接受了動脈血的取樣,谷值的定義為服藥前藥物濃度 (C0)。藥物動力學參數的計算是採用標準化
無房室模式,AUC0e24 的計算採用線性梯形方式。全血 tacrolimus 濃度的測量儀器,則是採用高
效能液相色層分析串聯質譜儀 (HPLCMS/MS)。
結果: 本研究共納入 14 位服用 Advagraf 的病人,平均 C0 為 4.4  1.9 ng/ml,平均 AUC0e24 為
143.8  57.0 ng$h/ml,平均最高濃度 Cmax 為 10.2  3.9 ng/ml,達到 Cmax 的時間中位數 tmax
則為 2.0 小時 (四分位數間距 1.0e3.0 小時);C0 與 AUC0e24 存在明顯的相關性 (r Z 0.90、p <
0.001)。在接受 diltiazem的病人中,平均 AUC0e24較高 (153.0  55.3 ng$h/ml vs. 110.1  60.1
ng$h/ml),即使他們服用較低的 tacrolimus劑量 (平均劑量 0.039  0.022 mg/kg/day vs. 0.054 
0.021 mg/kg/day);這兩種差異未達統計學意義。除了 C0之外,6至 12小時 (C6 to C12)之 tacro-
limus 濃度亦與 AUC0e24 存在顯著的相關性。
結論: 對於病情穩定的華裔 KTRs,tacrolimus 谷值乃 AUC0e24 的一個良好替代指標;至於 C6 to
C12 的角色則仍有待證實。Introduction
Tacrolimus, a calcineurin inhibitor (CNI), is commonly used
in solid organ transplantation. The latest Kidney Disease:
Improving Global Outcomes clinical practice guideline for
the care of kidney transplant recipients (KTRs) suggested
tacrolimus to be used as the first-line CNI.1 Tacrolimus was
first developed as a twice-daily oral formulation (tacroli-
mus-BID; Prograf, Astellas Pharma Hong Kong Co., Ltd.,
Hong Kong, China). Once-daily tacrolimus (tacrolimus-OD;
Advagraf, Astellas Pharma) was developed with an aim to
improve drug compliance and lower pill burden. In KTRs,
there are no significant differences between the two for-
mulations in terms of biopsy-proven acute rejection rate,
patient survival, and graft survival at 12 months.2
Tacrolimus-OD has also been shown to be associated with
better patient compliance,3 gastrointestinal tolerability,4
and possibly lower overall treatment cost per patient.5
Tacrolimus has a narrow therapeutic index and requires
therapeutic drug monitoring (TDM) in order to optimize
clinical outcome. Traditionally, area under the curve (AUC)
measurement is regarded as the gold standard of measuring
tacrolimus exposure.6 Nevertheless, routine AUC measure-
ment is both time-consuming and costly in daily clinical
practice. Tacrolimus trough level (Cmin) is usually used as a
surrogate indicator of drug exposure. However, the re-
ported correlation between Cmin and 12-hour AUC (AUC0e12)
was highly variable for tacrolimus-BID.7 In particular, the
Cmin of tacrolimus-BID did not have a significant correlation
with AUC0e12 in stable Chinese KTRs, leading to theoretical
concerns of extrapolating such recommendation to TDM of
tacrolimus-OD.8 In other population pharmacokinetic (PK)
studies, there was up to 50% variation in 24-hour AUC
(AUC0e24) for the same Cmin in patients receiving tacroli-
mus-OD.9e11 This has led to the suggestion of using drug
levels at 0 hours, 1 hour, and 3 hours after dose (C0, C1, and
C3, respectively) for better estimation of the AUC0e24.
9e11
Given the paucity of evidence regarding the best method
of TDM and unique genetic background of the Chinese
population, the objective of this study was to determine
whether Cmin is a good surrogate marker for TDM of Adva-
graf in stable Chinese KTRs.Methods
Patient selection
This was a prospective, single-center PK study involving
stable Chinese KTRs who were followed up in Prince of Wales
Hospital and taking tacrolimus-OD (Advagraf; Astellas
Pharma Hong Kong Co., Ltd.) as part of their maintenance
immunosuppressive regimen. Inclusion criteria included
adult KTRs aged 18 years, kidney transplant for more than
1 year, stable renal function (defined as <25% change in
serum creatinine) over the past 6 months, and no change of
tacrolimus dosage in the previous 1 month. Exclusion criteria
included significant liver impairment (defined as elevated
serum alanine aminotransferase level more than 2 times the
upper limit of normal), severe gastrointestinal disorder that
may affect drug absorption, and pregnancy. Clinical records
of recruited patients were reviewed for the collection of
baseline demographic and clinical data. The study was
approved by the local ethics committee, and all study pro-
cedures were in compliance with the Declaration of Helsinki.Sample collection and tacrolimus assay
After written informed consent was obtained, a 24-hour PK
study was performed for each patient. The study was car-
ried out in an outpatient setting on the day of the sched-
uled clinic follow-up. All patients were instructed to take
the drug on an empty stomach and swallow the whole
capsule with water in order to achieve maximal absorption.
Blood sampling was performed at 12 time points within
24 hours: 0 minute (i.e., before dose), 20 minutes, 40 mi-
nutes, 1 hour, 1.5 hour, 2 hours, 3 hours, 4 hours, 6 hours,
9 hours, 12 hours, and 24 hours. At each time point, 3 mL of
venous blood was drawn and stored in separate ethyl-
enediaminetetraacetic acid (EDTA) bottles. Venous blood
sampling was performed by a research nurse in a hospital
day ward. After blood taking for tacrolimus levels from
0 minute to 12 hours, patients were allowed to go home.
Patients were then instructed to come back the next
morning for blood taking to measure tacrolimus level at
Advagraf pharmacokinetic study 324 hours (C24). Whole blood tacrolimus level measurement
was performed using high-performance liquid chromatog-
raphy/tandem mass spectrophotometry.
Data and statistical analysis
PK parameters were calculated using standardized non-
compartmental methods. Maximum concentration (Cmax)
and time to reach Cmax (tmax) were obtained directly from
the blood concentrationetime curves. Trough level was
defined as the predose concentration at 0 minute (C0). The
AUC0e24 was calculated using the linear trapezoidal
method. Statistical analysis was performed using SPSS for
Windows software version 17.0 (SPSS Inc., Chicago, IL,
USA). Data are expressed as mean  standard deviation,
unless otherwise specified. Correlation between blood
concentrations measured at different time points and
AUC0e24 was assessed with the nonparametric Spearman’s
rank correlation coefficient (r). A p value < 0.05 was
considered statistically significant.Results
A total of 17 patients were identified, which represented all
KTRs receiving Advagraf in our center. Two patients refusedTable 1 Baseline demographic and clinical
characteristics.
Total number of patients 14
Male/female 8/6
Age (y) 47.1  9.2
Body height (cm) 163.2  11.1
Body weight (kg) 70.8  16.1
Systolic blood pressure (mmHg) 130  17
Diastolic blood pressure (mmHg) 76  14
Diabetes 3 (21.4%)
Hypertension 14 (100%)
Duration of kidney transplant (y) 8.3  3.6
Dosage of Advagraf (mg/kg/d) 0.042  0.022
Hemoglobin (g/dL) 12.9  1.8
Serum creatinine (mmol/L) 162  136
Serum albumin (g/L) 42.6  2.4
Total cholesterol (mmol/L) 4.9  0.9
LDL cholesterol (mmol/L) 2.7  0.8
HDL cholesterol (mmol/L) 1.6  0.4
Total triglyceride (mmol/L) 1.3  0.6
Fasting glucose (mmol/L) 5.2  0.9
Concomitant medications
Prednisolone þ Advagraf þ mycofenolatea 7 (50%)
Prednisolone þ Advagraf þ azathioprine 5 (35.7%)
Prednisolone þ Advagraf 2 (14.3%)
Diltiazem 11 (78.6%)
Beta-blocker 8 (57.1%)
Angiotensin converting enzyme inhibitor 1 (7.1%)
Angiotensin receptor blocker 5 (35.7%)
Histamine-2 receptor blocker 3 (21.4%)
HDLZ high-density lipoprotein; LDLZ low-density lipoprotein.
a Three patients were on mycophenolic acid delayed-release
(Myfortic), and four patients were on mycophenolate mofetil.to participate in the study. One patient was excluded
because of history of gastrectomy. Fourteen patients were
recruited and completed the study. The baseline de-
mographic and clinical characteristics are shown in Table 1.
No patients suffered from adverse events throughout the
study.
The mean maintenance dose of tacrolimus was
0.042  0.022 mg/kg/d. Tacrolimus exposure in each pa-
tient, expressed in form of whole-blood tacrolimus con-
centrationetime curve, is shown in Figure 1. The PKFigure 1 Pharmacokinetic profile of once-daily tacrolimus
expressed in the form of blood concentration time curve.
Table 2 Pharmacokinetic parameters of Advagraf.
Mean 24-h area under the curve, AUC0e24
(ng h/mL)
143.8  57.0
Mean maximum concentration, Cmax
(ng/mL)
10.2  3.9
Mean trough concentration, C0 (ng/mL) 4.4  1.9
Median time to maximum concentration,
tmax (h)
2.0 (1.0
e3.0)
AUC0e24 Z 24-hour area under the curve; C0 Z predose drug
level; Cmax Z mean maximum concentration; tmax Z time to
reach Cmax.
Table 3 Correlation between tacrolimus concentration at
different time points and 24-hour drug exposure.
Time point Spearman r (p)
0 min 0.90 (p < 0.001)
20 min 0.92 (p < 0.001)
40 min 0.78 (p Z 0.001)
60 min 0.70 (p Z 0.007)
90 min 0.69 (p Z 0.008)
2 h 0.77 (p Z 0.002)
3 h 0.74 (p Z 0.004)
4 h 0.86 (p < 0.001)
6 h 0.98 (p < 0.001)
10 h 0.94 (p < 0.001)
12 h 0.97 (p < 0.001)
24 h 0.85 (p < 0.001)
Figure 2 Correlation between tacrolimus trough level, C0,
and 24-hour area under curve (AUC0e24).
Table 4 Pharmacokinetic studies of once-daily tacrolimus in so
Study Year of
publication
Patients Num
pati
Hardinger et al18 2004 Stable KTRs > 6 mo 18
Alloway et al19 2005 Stable KTRs > 6 mo 66
van Hooff et al20 2012 Stable KTRs  6 mo 60
van Boekel et al21 2015 Stable KTRs 26
Wlodarczyk et al22 2009 De novo KTRs 34
Cabello et al23 2010 De novo KTRs aged  55 14
Wlodarczyk et al24 2012 De novo KTRs 17
Niioka et al25 2012 De novo KTRs 25
Tsuchiya et al26 2013 De novo KTRs 50
Satoh et al27 2014 De novo KTRs 24
Florman et al28 2005 LTRs > 6 mo with stable
renal and liver function
62
Zhang et al29 2011 LTRs 6e24 mo with
stable renal and liver
function
83
Fischer et al30 2011 De novo LTRs 45
Sugwara et al31 2011 De novo LTRs 9
Alloway et al32 2011 Stable heart transplant
patients > 6 mo
45
Me´ndez et al33 2014 Stable lung transplant
patients > 6 mo
19
KTRsZ kidney transplant recipients; LTRsZ liver transplant recipien
the curve.
4 T.K.-W. Ma et al.parameters are shown in Table 2. A target AUC0e24 of
125 ng h/mL has been recommended using the mean
population-based PK parameters of tacrolimus-BID, which
corresponds to a Cmin of 7.5 ng/mL (range, 5e15 ng/mL).
12
The mean AUC0e24 of our patients was 143.8  57.0 ng h/
mL, which corresponded to mean C0 of 4.4  1.9 ng/mL.
Patients receiving diltiazem had higher mean AUC0e24
(153.0  55.3 ng/mL vs. 110.1  60.1 ng h/mL) despite a
lower dose of tacrolimus (0.039  0.022 mg/kg/d vs.
0.054  0.021 mg/kg/d), although both differences did not
reach statistical significance. There was also a trend toward
higher C0 in patients receiving diltiazem (4.4  1.7 ng/mL
vs. 3.2  2.1 ng/mL). The correlation between tacrolimus
level at each time point and AUC0e24 is shown in Table 3.
There was a good correlation between C0 and AUC0e24
(r Z 0.90, p < 0.001). A graphical representation is shown
in Figure 2. Apart from C0, the tacrolimus level obtained
from 6 hours to 12 hours (C6 to C12) also had goodlid organ transplant recipients.
ber of
ents
Ethnicity Correlation between
Cmin and AUC0e24
Caucasians (89%),
African American (11%)
Day 14, r2 Z 0.77
Caucasian (80.3%),
African American
(18.2%), Asian (1.5%)
Day 14, rZ 0.92; Day 21,
r Z 0.86
Caucasian (75.0%), Black
(1.7%)
Asian (13.3%), others
(10%)
Day 28, rZ 0.89; Day 56,
r Z 0.82
Caucasian (100%) r Z 0.83
Caucasian (96.7%),
others (3.3%)
Days 1, 14, and 42
(combined), r Z 0.83
White (100%) Day 3, r Z 0.87; Day 21,
r Z 0.83
White (94.1%), other
(5.9%)
Days 1, 3, 7, and 14
(combined), r Z 0.87
Japanese (100%) Day 28, r Z 0.64
Japanese (100%) Day 14, r Z 0.94
Japanese (100%) Prior to transplant,
r2 Z 0.70; 1 mo,
r2Z 0.71; 1 y, r2 Z 0.86
Caucasian (91.9%),
African American (6.5%),
Pacific Islander (1.6%)
Day 28, rZ 0.90; Day 56,
r Z 0.88
Chinese (100%) Day 1, r Z 0.94; Day 84,
r Z 0.90
Caucasian (100%) Days 1, 14, and 42
(combined), r Z 0.92
Japanese (100%) Day 7, r Z 0.49
White (91.1%), Black
(8.9%)
Days 14 and 21
(combined), r Z 0.94
Not mentioned Days 14e28, r Z 0.96
ts; CminZ tacrolimus trough level; AUC0e24Z 24-hour area under
Advagraf pharmacokinetic study 5correlation with the AUC0e24. As shown in Figure 1, tacro-
limus levels were relatively stable from 6 hours to 12 hours.Discussion
Tacrolimus-OD is increasingly used in solid organ transplant
recipients in recent years. It has a longer tmax than
tacrolimus-BID, but AUC0e24 is similar.
13,14 Apart from
potentially better drug compliance and lower pill burden,
tacrolimus-OD has been shown to be associated with
improved graft outcome, glucose tolerance, and lipid
profile.15e17 Tacrolimus has a narrow therapeutic index.
Underdosing is associated with an increased risk for graft
rejection, whereas overdosing is associated an increased
risk for CNI toxicity. Therefore, a reliable method of TDM is
of paramount importance to optimize clinical outcome.
The PK studies of tacrolimus-OD have been conducted in
solid organ transplant recipients of different ethnicities.
These included stable KTRs,18e21 de novo KTRs,22e27 stable
liver transplant recipients (LTRs),28,29 de novo LTRs,30,31
stable heart transplant recipients,32 and stable lung trans-
plant recipients.33 The key findings of these studies are
summarized in Table 4. The reported correlation between
C0 and AUC0e24 was variable, with the correlation coeffi-
cient ranging from 0.4931 to 0.96.33 There was only one PK
study in the literature involving Chinese population.29 In
this prospective, open-label, multicenter study, 83 stable
LTRs were converted from tacrolimus-BID to tacrolimus-OD
on a 1 mg:1 mg basis. Two separate PK studies were con-
ducted after switching to tacrolimus-OD on Day 1 and Day
84. There was a good correlation between C0 and AUC0e24
on both days (Day 1, r Z 0.94; Day 84, r Z 0.90).
Our study is the first PK study of tacrolimus-OD in stable
Chinese KTRs in a real-life clinical setting. Our patients
have been transplanted for a mean of 8.3 years. The mean
duration of tacrolimus-OD use was 3.6 years. All patients
had stable graft function without recent change of drug
dosage. This helped to ensure that the PK profiles were
obtained after the establishment of a steady state of drug
absorption and metabolism. We found a strong correlation
between C0 and AUC0e24. Compared with the previous study
by Zhang et al,29 our patients received a lower dose of
tacrolimus (0.042  0.022 mg/kg/d vs. 0.072  0.035 mg/
kg/d), but achieved a higher level of C0 (4.4  1.9 ng/mL
vs. 3.3  1.5 ng/mL) and AUC0e24 (143.8  57.0 ng h/mL vs.
113  44 ng h/mL). This may be explained by the high
percentage of diltiazem (a potent cytochrome P450 enzyme
inhibitor) use in our cohort. In patients not receiving dilti-
azem in our cohort, the AUC0e24 was comparable with that
reported by Zhang et al29 (110.1  60.1 ng h/mL vs.
113  44 ng h/mL).
Using Cmin for TDM, despite allowing standardized com-
parison between patients, may not be always practical in a
busy clinical setting. van Boekel et al21 recently performed
a prospective, extended PK studies in 26 stable Caucasian
KTRs. Instead of the traditional venous sampling method,
the investigators used a validated dried blood spot method
for sampling and analysis of tacrolimus level. Patients were
trained to perform finger prick with an automatic lancet
and take their own blood samples at home. Capillary blood
sampling was performed at 10 different time points up to32 hours. The correlation coefficients between drug level
taken at 24 hours to 32 hours and AUC0e24 ranged from 0.82
to 0.88 (p < 0.01 for all). The authors suggested that the
use of delayed drug levels could be considered for TDM,
especially for patients who have clinic follow-up in the
afternoon. However, the effect of delaying tacrolimus
intake for the purpose of blood taking could be a potential
concern.
In our study, there was excellent correlation between C6
to C12 and AUC0e24. Any delay in taking tacrolimus could be
avoided if these time points could be used for TDM. It
should be stressed, however, that currently there is no
recommendation from the pharmaceutical company or
clinical trials on the desirable range of tacrolimus level if
time points other than the trough level are used for TDM.
The effect on clinical outcome is also uncertain.
There are several limitations in our study. The sample
size was small. We included only KTRs who were switched
from tacrolimus-BID to tacrolimus-OD, whether using Cmin is
appropriate for TDM in de novo Chinese KTRs could be
ascertained. The PK profile of tacrolimus is influenced by
the patients’ cytochrome P450 isoenzymes 3A4 and 3A5
(CYP3A4 and CYPA3A5) genotype status.34e37 We do not
have the data on CYP3A4 and CYP3A5 genetic poly-
morphisms in our patients. However, even if such infor-
mation is available, its potential effect on PK profile is
grossly confounded because of the high percentage of dil-
tiazem use. We do not have renal biopsy data to correlate
the degree of immunosuppression as reflected by tacroli-
mus AUC24 with the presence of subclinical rejection or CNI-
induced chronic allograft injury.
Conclusion
This marks the first PK study of Advagraf in stable Chinese
KTRs that showed that tacrolimus trough level could be
safely used for TDM. Further studies are required to
determine the role of TDM using C6 to C12.
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